Sells medicines for cancer, immune diseases, and infections through distributors to health care providers in Greater China.
10-K for FY2025, filed Feb 26, 2026We are a patient-focused, innovative, commercial-stage, global biopharmaceutical company with a substantial presence in both Greater China…View ↗
We currently have seven commercial programs with products that have received marketing approval and that we have commercially launched in…View ↗
We rely on independent third-party distributors in Greater China to sell our commercial products, which is consistent with the…View ↗
The company earns money mainly by selling commercial medicines to distributors in Greater China; payment generally follows delivery within a year. It also earns collaboration revenue from promotional activities.
10-K for FY2025, filed Feb 26, 2026The Company’s revenue is mainly from product sales. The Company recognizes revenue from product sales when the Company has satisfied the…View ↗
The Company has applied the practical expedients under ASC 606 with regard to assessment of the financing component and concluded that…View ↗
In mainland China, the Company sells these products to distributors, who ultimately sell the products to health care providers. Based on…View ↗
Collaboration revenue was $3.0 million, $1.4 million, and nil in 2025, 2024, and 2023, respectively, and related to promotional activities…View ↗
10-K for FY2025, filed Feb 26, 2026
FY2025 revenue by product or service (Product revenue, net) ↗$460.2M
10-K for FY2025, filed Feb 26, 2026
$460.2M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
ZEJULA
Sold outright
10-K for FY2025, filed Feb 26, 2026 |
41%
FY2022: 68%
|
ZEJULA, FY2025
$189M Sources
|
Sold outright |
|
VYVGART / VYVGART Hytrulo
Sold outright
10-K for FY2025, filed Feb 26, 2026 |
21%
FY2022: 0.0%
|
VYVGART / VYVGART Hytrulo, FY2025
$94.2M Sources
|
Sold outright |
|
NUZYRA
Sold outright
10-K for FY2025, filed Feb 26, 2026 |
13%
FY2022: 2.5%
|
NUZYRA, FY2025
$60.8M Sources
|
Sold outright |
|
OPTUNE
Sold outright
10-K for FY2025, filed Feb 26, 2026 |
11%
FY2022: 22%
|
OPTUNE, FY2025
$48.3M Sources
|
Sold outright |
|
QINLOCK
Sold outright
|
7.8%
FY2022: 7.0%
|
QINLOCK, FY2025
$35.6M Sources
|
Sold outright |
|
XACDURO
Sold outright
|
5.0%
FY2022: 0.0%
|
XACDURO, FY2025
$22.9M Sources
|
Sold outright |
|
AUGTYRO
Sold outright
|
1.2%
FY2022: 0.0%
|
AUGTYRO, FY2025
$5.5M Sources
|
Sold outright |
|
Other
Sold outright
|
0.2% |
Other, FY2025
$717K Sources
|
Sold outright |
The company sells its commercial products to independent third-party distributors in Greater China, who then sell them to health care providers.
10-K for FY2025, filed Feb 26, 2026We rely on independent third-party distributors in Greater China to sell our commercial products, which is consistent with the…View ↗
10-K for FY2025, filed Feb 26, 2026
In 2025, 2024, and 2023, the Company’s five largest customers accounted for approximately $151.5 million (33.1%), $128.7 million (32.4%)…View ↗
No. It lost $175.5M in FY2025.
10-Q for Q3 FY2026, filed Nov 5, 2026
−$46.1MView ↗
10-Q for Q3 FY2026, filed Nov 5, 2026
Open tableView ↗
Growing. Revenue grew 3.2x in 4 years, from $144.3M in FY2021 to $460.2M in FY2025, about 34% a year.
Broader commercial portfolio
The commercial portfolio has broadened beyond ZEJULA, Optune, QINLOCK, and NUZYRA to include VYVGART / VYVGART Hytrulo, XACDURO, and AUGTYRO.
10-K for FY2022, filed Mar 1, 2023received approval for and commercialized four products (ZEJULA, Optune, QINLOCK, and NUZYRA); expanded our pipeline to increase our product…View ↗
Loading...